Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore,...
Main Authors: | Tsai-Hung Yen, Chung-Hsin Chang, Sz-Iuan Shiu |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-07-01
|
Series: | Case Reports in Gastroenterology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/508583 |
Similar Items
-
Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
by: Sardar Zakariya Imam, et al.
Published: (2020-09-01) -
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01) -
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
by: Hsu CH, et al.
Published: (2014-06-01) -
The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment
by: Ming‐Lun Yeh, et al.
Published: (2019-10-01) -
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01)